Fiche publication
Date publication
juin 2020
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
,
Dr MOUILLET Guillaume
Tous les auteurs :
Gassian N, Frontczak A, El Kaddissi A, Calcagno F, Almotlak H, Barkatz J, Mouillet G, Maurina T, Stein U, Nguyen Tan Hon T, Murez T, Thiery-Vuillemin A
Lien Pubmed
Résumé
Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.
Mots clés
Cancer du pénis, Chemotherapy, Chimiothérapie, Immunotherapy, Immunothérapie, Penile cancer, Targeted therapy, Thérapie ciblée
Référence
Bull Cancer. 2020 Jun;107(5S):S17-S23
